| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie |
NCT00404573: Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia |
|
|
| Completed | 2 | 375 | US | RGH-188 | Forest Laboratories | Schizophrenia | 08/07 | | | |
|
NCT00488618: Study Evaluating Cariprazine (RGH-188) in the Treatment of Patients With Acute Mania |
|
|
| Completed | 2 | 238 | US | Cariprazine (RGH-188), Placebo | Forest Laboratories, Gedeon Richter Ltd. | Bipolar Disorder | 07/08 | 07/08 | | |
NCT00694707: Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia |
|
|
| Completed | 2 | 732 | US, RoW | Placebo, Cariprazine, RGH-188, Risperidone, Risperdal | Forest Laboratories, Gedeon Richter Ltd. | Schizophrenia | 08/09 | 08/09 | | |
|
NCT00862992: Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia |
|
|
| Completed | 2 | 34 | Japan | Cariprazine 3 mg, Cariprazine(INN), RGH-188, Cariprazine 6 mg, Cariprazine 12.5 mg | Tanabe Pharma Corporation | Schizophrenia | 09/09 | 09/09 | | |
NCT00852202: Safety and Efficacy of RGH-188 (Cariprazine) in Bipolar Depression |
|
|
| Completed | 2 | 234 | US | cariprazine, placebo | Forest Laboratories, Gedeon Richter Ltd. | Bipolar Depression | 06/10 | 06/10 | | |
NCT00839852: A Study of Cariprazine in Patients With Chronic Stable Schizophrenia |
|
|
| Completed | 2 | 97 | US, RoW | Cariprazine, RGH-188 | Forest Laboratories, Gedeon Richter Ltd. | Schizophrenia | 08/10 | 08/10 | | |
NCT00854100: Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder |
|
|
| Completed | 2 | 231 | US | Antidepressant + placebo, Antidepressant + cariprazine (0.1-0.3 mg/day), Antidepressant + cariprazine (1-2 mg/d) | Forest Laboratories, Gedeon Richter Ltd. | Major Depressive Disorder | 12/10 | 12/10 | | |
NCT03605784: Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder |
|
|
| Completed | 2 | 232 | US | Antidepressant + placebo, Antidepressant + cariprazine (0.1-0.3 mg/day), Antidepressant + cariprazine (1-2 mg/d) | Allergan, Gedeon Richter Ltd. | Major Depressive Disorder | 12/10 | 12/10 | | |
| Completed | 2 | 819 | US, Europe, RoW | Placebo, Cariprazine | Forest Laboratories, Gedeon Richter Ltd. | Major Depressive Disorder | 12/13 | 12/13 | | |
| Completed | 2 | 584 | US, Canada, Europe, RoW | Placebo, Cariprazine | Forest Laboratories, Gedeon Richter Ltd. | Depression, Bipolar | 01/14 | 01/14 | | |
NCT03430544: Cariprazine Effects on Brain and Behavior in Cocaine Use Disorder |
|
|
| Terminated | 2 | 14 | US | Cariprazine Oral Capsule [Vraylar], Placebo oral capsule | Anna Rose Childress, Ph.D., National Institute on Drug Abuse (NIDA) | Cocaine Use Disorder | 09/20 | 09/20 | | |
CAR aGAD Ph 2, NCT04965272: A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone |
|
|
| Withdrawn | 2 | 0 | US | Cariprazine 0.75 mg/day, Vraylar, Cariprazine 1.5 mg/day, Cariprazine 3.0 mg/day, Placebo | AbbVie | Generalized Anxiety Disorder | 08/21 | 08/21 | | |
NCT05063201: Cariprazine for Comorbid Cocaine and Opioid Use Disorder |
|
|
| Recruiting | 2 | 48 | US | Cariprazine 1.5 MG, Placebo | Kyle Kampman, National Institute on Drug Abuse (NIDA) | Opioid-use Disorder, Cocaine Use Disorder | 12/25 | 12/25 | | |
NCT07185815: Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine |
|
|
| Recruiting | 1/2 | 24 | RoW | Cariprazine Depot, Cariprazine Depot MTD, Oral Cariprazine 3 mg/day | Mapi Pharma Ltd. | Major Depressive Disorder (MDD), Bipolar 1 Disorder, Schizophrenia | 12/26 | 06/27 | | |
